Actipulse Neuroscience Announces Successful Clinical Trial Using Fast Gamma Magnetic Stimulation for the Treatment of Alzheimer’s Disease

This trial marks the first step taken by Actipulse Neuroscience to use a new method of neuromodulation to stop or slow Alzheimer's disease, an issue that fails to be solved by anything currently available on the market

Today, the results of a recent pilot clinical trial, funded by neurotech company Actipulse Neuroscience, have demonstrated that its non-invasive intervention devices, using Fast Gamma Magnetic Stimulation (FGMS), can be safely administered to patients with mild Alzheimer’s disease.

Actipulse Neuroscience’s proprietary transcranial neuromodulation is based on previously developed FDA-approved technology, which applies high-frequency and low-intensity magnetic pulses directly to the skull using a wearable headset.

The details of this randomized, double-blind, sham-controlled study were published in the leading industry journal Frontiers in Neurology. It states that 34 participants, with mild cognitive impairment or mild Alzheimer’s disease, were split into two groups. Each of them received either active or sham FGMS over the left prefrontal dorsolateral cortex twice a day for six months. After this period, the participants were tested for adverse effects, cognitive activity, functionality, and depression.

The results show that FGMS was adequately tolerated by most of the subjects, with only five presenting any kind of adverse effects. This concludes that FGMS applied in this way is a viable intervention that can be safely used at home, without healthcare provider supervision.

Since 2003, no new drug with clinically proven results has been approved for the treatment of Alzheimer’s disease, and there have been more than 400 failed clinical trials. But the success of this first pilot trial, proving the safety of this neurostimulation device, means that Actipulse Neuroscience will be able to move onto the next phase. A second trial, focusing on efficacy, will take place in the first quarter of 2022.

This is part of Actipulse’s long-term goal of providing accessible worldwide state-of-the-art technology that can be administered at home, without a healthcare provider, offering patients suffering from neurodegenerative diseases more independence over their health.

“We are extremely happy with the results from this safety trial and are eager to start the efficacy study with the hope of finding a new method to slow disease progression,” said Adrien Châtillon, Chief Executive Officer and co-founder of Actipulse Neuroscience.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  

By using this website you agree to accept Medical Device News Magazine Privacy Policy